[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insmed Inc (INSM)

Insmed Inc (INSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,656,312
  • Shares Outstanding, K 216,752
  • Annual Sales, $ 606,420 K
  • Annual Income, $ -1,277 M
  • EBIT $ -1,145 M
  • EBITDA $ -1,120 M
  • 60-Month Beta 0.89
  • Price/Sales 41.33
  • Price/Cash Flow N/A
  • Price/Book 35.41

Options Overview Details

View History
  • Implied Volatility 50.41% (-0.86%)
  • Historical Volatility 90.15%
  • IV Percentile 46%
  • IV Rank 30.31%
  • IV High 89.51% on 12/17/25
  • IV Low 33.42% on 09/11/25
  • Expected Move (DTE 32) 10.46 (9.58%)
  • Put/Call Vol Ratio 3.68
  • Today's Volume 3,531
  • Volume Avg (30-Day) 5,120
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 102,870
  • Open Int (30-Day) 57,019
  • Expected Range 98.69 to 119.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 9
  • High Estimate $-0.59
  • Low Estimate $-1.06
  • Prior Year $-1.70
  • Growth Rate Est. (year over year) +55.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
98.90 +10.35%
on 05/11/26
146.18 -25.34%
on 04/16/26
-37.60 (-25.62%)
since 04/15/26
3-Month
98.90 +10.35%
on 05/11/26
167.37 -34.79%
on 02/20/26
-39.61 (-26.63%)
since 02/13/26
52-Week
64.85 +68.31%
on 05/22/25
212.75 -48.70%
on 12/02/25
+41.92 (+62.36%)
since 05/15/25

Most Recent Stories

More News
S&P Futures Climb With All Eyes on Key U.S. Jobs Report

June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report.

ESM26 : 7,432.25s (-1.24%)
QCOM : 201.49 (+0.70%)
TTD : 21.15 (+3.63%)
DDOG : 207.98 (+2.53%)
IAG.LN : 375.910 (-2.21%)
ZTS : 74.22 (-1.67%)
AKAM : 150.88 (-3.08%)
XYZ : 70.36 (-1.64%)
RKLB : 124.77 (-5.87%)
RHM.D.DX : 1,121.500 (-1.99%)
ARM : 209.16 (-8.46%)
INSM : 109.14 (-5.60%)
Insmed Q1 Earnings Call Highlights

Insmed (NASDAQ:INSM) executives said the company entered 2026 with strong commercial momentum for BRINSUPRI and continued growth for ARIKAYCE, while advancing late-stage development of TPIP across multiple...

INSM : 109.14 (-5.60%)
Stocks Fall on Doubts About an Imminent US-Iran Peace Deal

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.38%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.12%. June...

AMAT : 436.62 (-0.89%)
APP : 501.00 (+3.26%)
AVGO : 425.19 (-3.32%)
SNDK : 1,407.61 (+1.80%)
INTU : 393.00 (+3.89%)
DDOG : 207.98 (+2.53%)
$IUXX : 29,125.20 (-1.54%)
DASH : 159.20 (+3.58%)
ZNM26 : 109-055s (-0.85%)
MKSI : 303.17 (-3.39%)
ESM26 : 7,432.25s (-1.24%)
WDC : 482.02 (-1.46%)
S&P 500 Reverses After Hitting Record High as Oil Prices Bounce Back

The S&P 500 Index ($SPX ) (SPY ) today is down -0.40%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. Equity markets retreated...

MPC : 255.03 (+2.50%)
APP : 501.00 (+3.26%)
INTU : 393.00 (+3.89%)
CVX : 191.10 (+2.39%)
DDOG : 207.98 (+2.53%)
SLB : 55.38 (-0.66%)
DASH : 159.20 (+3.58%)
$IUXX : 29,125.20 (-1.54%)
ZNM26 : 109-055s (-0.85%)
MSFT : 421.92 (+3.05%)
MKSI : 303.17 (-3.39%)
OXY : 59.62 (+4.89%)
Stocks Mixed Awaiting an Iran Update

The S&P 500 Index ($SPX ) (SPY ) today is down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. June E-mini S&P futures (ESM26...

MPC : 255.03 (+2.50%)
INTU : 393.00 (+3.89%)
DDOG : 207.98 (+2.53%)
SLB : 55.38 (-0.66%)
$IUXX : 29,125.20 (-1.54%)
DASH : 159.20 (+3.58%)
ZNM26 : 109-055s (-0.85%)
MSFT : 421.92 (+3.05%)
MKSI : 303.17 (-3.39%)
OXY : 59.62 (+4.89%)
ESM26 : 7,432.25s (-1.24%)
FANG : 203.56 (+1.65%)
Insmed: Q1 Earnings Snapshot

Insmed: Q1 Earnings Snapshot

INSM : 109.14 (-5.60%)
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

— Total Company Revenues of $306.0 Million for the First Quarter of 2026—

INSM : 109.14 (-5.60%)
Insmed's Path to Profitability Faces Its First Real Test This Week

Barchart Research What to Expect from INSM Earnings INSM Generated May 6, 2026 Current Price $137.09 EPS Estimate $$-0.90 Consensus Rating Strong Buy Average Move 4.46% Insmed's Path to Profitability Faces...

INSM : 109.14 (-5.60%)
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

— Insmed's Educational Initiative, Suspect Bronchiectasis  (Suspect BE) , Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — ...

INSM : 109.14 (-5.60%)
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms—

INSM : 109.14 (-5.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 119.32
2nd Resistance Point 116.91
1st Resistance Point 113.03
Last Price 109.14
1st Support Level 106.74
2nd Support Level 104.33
3rd Support Level 100.45

See More

52-Week High 212.75
Fibonacci 61.8% 156.25
Fibonacci 50% 138.80
Fibonacci 38.2% 121.34
Last Price 109.14
52-Week Low 64.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.